Insulet (PODD) Stock

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® products, has announced that it will share its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the markets close. On that day, management will also hold a conference call at 4:30 p.m. (Eastern Time). A link to the live call will be provided.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the best features of the Zacks Premium research service.

PODD stock remains a focus for investors because of its strong advancements with Omnipod 5 and its significant opportunities in the diabetes market.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® products, has successfully protected its intellectual property against EOFlow Co., Ltd. in federal court. Following a four-week trial in the U.S. District Court for the District of Massachusetts, the jury ruled in favor of Insulet.

Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.

Insulet's Omnipod 5 System can now work with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.

Insulet's stock has increased by over 50% in the last six months, thanks to strong earnings in the third quarter and the approval of Omnipod 5 for Type 2 diabetes, which opens up new market opportunities. However, the company faces challenges from high market expectations and competition from major players like Medtronic and Abbott, which could impact its future success. While Insulet's financial situation is strong, with growing revenues and profits, the high stock price requires ongoing impressive growth to justify it.

Insulet Corporation, known for its Omnipod® tubeless insulin pump technology, has announced that its management will speak at three investor conferences. These events include the 6th Annual Wolfe Research Healthcare Conference in New York City on November 20, 2024, and the Nasdaq 51st Investor Conference in London on December 10, 2024.

Jim Hollingshead, the CEO of Insulet, appears on 'Closing Bell: Overtime' to talk about the company's earnings, the Apple app for blood sugar testing, and other topics.